Data Sheet (Cat.No.T10435)

TargetMol

Linaprazan

Chemical Properties



CAS No. : 248919-64-4

Formula: C21H26N4O2

Molecular Weight: 366.46

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Linaprazan (AZD0865) inhibits gastric H+,K+-ATPase through K+-competitive binding, with an IC50 of 1.0 μM.
Targets(IC50)	Proton pump,Potassium Channel
In vitro	Linaprazan (AZD0865) can inhibit the final step in acid secretion. Linaprazanreduced porcine renal Na+, K+-ATPase activity by 9 ± 2% [1].
In vivo	The reference for animal administration is 0.5-1.0 mg/kg. The greater degree of acid suppression with the 75-mg dose of Linaprazan would translate to a healing rate of 89% at 4 weeks [2].

Solubility Information

Solubility	DMSO: 3.67 mg/mL (10.01 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.73 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.7288 mL	13.6441 mL	27.2881 mL
5 mM	0.5458 mL	2.7288 mL	5.4576 mL
10 mM	0.2729 mL	1.3644 mL	2.7288 mL
50 mM	0.0546 mL	0.2729 mL	0.5458 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Gedda K et al. Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase. Biochem Pharmacol. 2007 Jan 15;73(2):198-205.
Kahrilas PJ et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol. 2007 Dec;5(12):1385-91.